Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - zonisamid - 21 - antiepileptica, anticonvulsiva

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - zonisamid - 21 - antiepileptica, anticonvulsiva

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica

Avrupa Birliği - Slovakça - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastické činidlá - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica